​

Ascendis Pharma (ASND) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

ASND Stock Forecast

Ascendis Pharma (ASND) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $320.27, with a high of $345.00 and a low of $273.00. This represents a 22.80% increase from the last price of $260.81.

$100 $150 $200 $250 $300 $350 High: $345 Avg: $320.27 Low: $273 Last Closed Price: $260.81

ASND Stock Rating

Ascendis Pharma stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 23 Buy (92.00%), 2 Hold (8.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 0 2 23 Strong Sell Sell Hold Buy Strong Buy

ASND Price Target Upside V Benchmarks

TypeNameUpside
StockAscendis Pharma22.80%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts111332
Avg Price Target$322.36$315.46$303.25
Last Closing Price$260.81$260.81$260.81
Upside/Downside23.60%20.95%16.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26416---20
Aug, 26414---18
Jul, 26414---18
Jun, 26413---17
May, 2612---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2026H.C. Wainwright$344.00$260.8131.90%31.90%
Sep 01, 2026Leland GershellOppenheimer$312.00$260.2519.88%19.63%
Sep 01, 2026Maxwell SkorMorgan Stanley$273.00$263.043.79%4.67%
Aug 31, 2026Jefferies$330.00$265.2624.41%26.53%
Aug 31, 2026Stifel Nicolaus$326.00$265.3222.87%25.00%
Aug 31, 2026UBS$345.00$247.9139.16%32.28%
Aug 27, 2026H.C. Wainwright$345.00$250.2537.86%32.28%
Aug 18, 2026BMO Capital$319.00$248.8528.19%22.31%
Aug 14, 2026Luca IssiRBC Capital$290.00$247.0717.38%11.19%
Aug 14, 2026Barclays$329.00$246.2333.61%26.15%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 10, 2026Cowen & Co.BuyBuyhold
Sep 10, 2026BMO CapitalOutperformOutperformhold
Sep 01, 2026OppenheimerOutperformOutperformhold
Sep 01, 2026Morgan StanleyOverweightOverweighthold
Sep 01, 2026Bank of America SecuritiesBuyBuyhold
Aug 31, 2026H.C. WainwrightBuyBuyhold
Aug 27, 2026H.C. WainwrightBuyinitialise
Aug 18, 2026BMO CapitalOutperforminitialise
Aug 14, 2026RBC CapitalOutperformOutperformhold
Aug 14, 2026Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-6 $3 $12 $21 $30 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.00$-10.40$-8.55-----
Avg Forecast$-7.41$-9.55$-8.86$-6.98$-3.90$1.06$10.04$13.91
High Forecast$-6.04$-7.77$-7.55$-5.72$-1.46$5.22$26.67$21.09
Low Forecast$-10.50$-14.59$-10.95$-7.73$-6.36$-0.88$3.69$10.79
Surprise %-5.53%8.90%-3.50%-----

Revenue Forecast

$0 $700M $1B $2B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.78M$51.17M$266.72M-----
Avg Forecast$6.60M$45.90M$224.61M$300.07M$530.08M$1.00B$1.73B$2.32B
High Forecast$8.71M$64.54M$279.10M$365.49M$749.98M$1.01B$2.41B$3.24B
Low Forecast$5.66M$39.31M$194.11M$258.44M$448.72M$996.14M$1.43B$1.92B
Surprise %17.89%11.49%18.75%-----

Net Income Forecast

$-1B $-400M $200M $800M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-383.58M$-583.19M$-481.45M-----
Avg Forecast$-417.32M$-537.67M$-437.49M$-381.83M$-196.74M$137.26M$538.04M$782.81M
High Forecast$-340.10M$-437.37M$-425.03M$-322.10M$-82.43M$293.94M$1.50B$1.19B
Low Forecast$-590.82M$-821.49M$-616.22M$-435.36M$-357.87M$-49.59M$207.64M$607.46M
Surprise %-8.08%8.47%10.05%-----

ASND Forecast FAQ

Is Ascendis Pharma stock a buy?

Ascendis Pharma stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 23 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Ascendis Pharma is a favorable investment for most analysts.

What is Ascendis Pharma's price target?

Ascendis Pharma's price target, set by 25 Wall Street analysts, averages $320.27 over the next 12 months. The price target range spans from $273 at the low end to $345 at the high end, suggesting a potential 22.80% change from the previous closing price of $260.81.

How does Ascendis Pharma stock forecast compare to its benchmarks?

Ascendis Pharma's stock forecast shows a 22.80% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Ascendis Pharma over the past three months?

  • September 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Ascendis Pharma’s EPS forecast?

Ascendis Pharma's average annual EPS forecast for its fiscal year ending in December 2024 is $-6.98, marking a -18.36% decrease from the reported $-8.55 in 2023. Estimates for the following years are $-3.9 in 2025, $1.06 in 2026, $10.04 in 2027, and $13.91 in 2028.

What is Ascendis Pharma’s revenue forecast?

Ascendis Pharma's average annual revenue forecast for its fiscal year ending in December 2024 is $300.07M, reflecting a 12.50% increase from the reported $266.72M in 2023. The forecast for 2025 is $530.08M, followed by $1B for 2026, $1.73B for 2027, and $2.32B for 2028.

What is Ascendis Pharma’s net income forecast?

Ascendis Pharma's net income forecast for the fiscal year ending in December 2024 stands at $-382M, representing a -20.69% decrease from the reported $-481M in 2023. Projections indicate $-197M in 2025, $137.26M in 2026, $538.04M in 2027, and $782.81M in 2028.